Skip to content
Calculator
Guide

Cerebrolysin: the stroke drug sold as a nootropic

Last updated: October 27, 2026 · 9 min read · By the Grey Peptides Editorial Board

Intravenous fluid bags hanging in front of medical imaging screens in a hospital
Photo by Furkan İnce on Pexels
Grey Peptides
Grey Peptides Editorial Board
Every status on this page carries the date it was checked. How we work
Key takeaways
  • Cerebrolysin is a peptide mixture from pig brain, given by intravenous infusion in hospitals in parts of Europe and Asia. It is not FDA-approved.
  • The 2023 Cochrane review of stroke trials found it does not reduce deaths and may increase non-fatal serious adverse events.
  • Smaller trials report benefits on recovery scores after stroke and brain injury; the manufacturer supported three of the stroke trials Cochrane pooled, and the evidence in dementia is mixed.
  • In healthy people only two small studies from 1998 and 2000 measured brain waves and short-term memory after it; no trial has tested it as a memory or focus treatment for healthy people.

What cerebrolysin is

Cerebrolysin is not a single peptide. The Cochrane review describes it as a mixture of low-molecular-weight peptides and amino acids derived from pig brain, with potential neuroprotective properties 1. In the trials below it was given as daily intravenous infusions for 10 to 30 days 2 3 4.

The 2017 edition of the Cochrane review records that it is widely used for acute stroke in Russia, Eastern Europe, China and other Asian and post-Soviet countries, and names the maker as EVER Neuro Pharma, formerly Ebewe Pharma 5. It is not approved by FDA or centrally authorised in the European Union 6. In rats with stroke, it increased the number of new nerve-cell precursors and cut dying cells at the edge of the damage by about half (animal evidence) 7.

How a stroke drug became a 'nootropic'

The trials on this page were all in people with stroke, brain injury or dementia, and they measured recovery from illness, not enhancement. A PubMed search on October 27, 2026 found two small studies in healthy people. In a 1998 randomised trial, 48 healthy men received placebo or 10, 30 or 50 mL infusions for 10 days; the authors reported changes in brain-wave power and a trend in short-term word recall, mild signs of overdose at the highest doses, and a small fall in blood pressure at the highest dose (randomised trial evidence) 8. In 2000, a single 30 mL oral dose in healthy elderly people was followed by more alpha brain-wave activity and fewer errors on memory items, with no placebo group reported in the abstract 9. Neither tested whether weeks of use improve memory, focus or mood in daily life. Evidence grade for nootropic use: very low.

Stroke: what the biggest studies found

The Cochrane review, updated in 2023, is the pooled summary. It pooled seven randomised trials with 1,773 people that started cerebrolysin, or a similar cattle-brain product called Cortexin, within 48 hours of stroke. The result: little to no difference in death from any cause (risk ratio 0.96; moderate-certainty evidence), little to no difference in the total number of people with serious adverse events, but an increase in non-fatal serious adverse events (risk ratio 2.39, 95% CI 1.10 to 5.23), most clearly at the common schedule of 30 mL a day for ten days. The reviewers judged the risk of bias unclear in most domains and high for incomplete outcome data in four of the seven trials, noted that the manufacturer supported three of the multicentre trials, and found that no trial reported death or dependence, quality of life or return to work 1.

The largest single trial, CASTA, randomised 1,070 people in Asia within 12 hours of stroke to cerebrolysin or saline for ten days on top of aspirin. Its primary outcome, a combined test of three stroke scales at 90 days, showed no significant difference. A subgroup analysis done afterwards suggested better outcomes and lower 90-day mortality (10.5% against 20.2%) in people with severe strokes, but subgroup findings found after the fact need confirming in a new trial before they can be trusted (randomised trial evidence) 2.

Stroke recovery: the smaller trials

Two smaller trials focused on recovery rather than survival. In CARS, people who started 30 mL a day for 21 days, 24 to 72 hours after stroke, alongside standard rehabilitation, had better arm function at 90 days, with a large effect on the main arm test and a small-to-medium effect across 12 scales (randomised trial evidence) 3. In another trial of 100 people treated within 18 hours, those on cerebrolysin had a larger improvement on the NIH Stroke Scale at 30 days; one of its authors worked for the manufacturer, EVER Neuro Pharma (randomised trial evidence) 4. CARS's authors called it exploratory and asked for a large trial to confirm it 3.

Both trials reported Mann-Whitney effect sizes rather than the share of patients who recovered. The one large trial, CASTA, missed its main outcome 2.

Traumatic brain injury

The CAPTAIN trials tested cerebrolysin after moderate to severe traumatic brain injury, alongside usual care. CAPTAIN I, with 46 patients, just missed statistical significance on its combined primary measure of 14 scales, though three individual tests favoured cerebrolysin (randomised trial evidence) 10. CAPTAIN II, with 139 analysed, found a small-to-medium effect at 90 days on a combined measure of 13 scales (randomised trial evidence) 11. A prospective meta-analysis of the two, 185 patients in all, reported small-to-medium effects at days 30 and 90 12.

These trials are small, and the combined-scale method spreads the benefit across many measures rather than showing it on one clinical outcome. All three reports share authors at the RoNeuro Institute in Cluj-Napoca, Romania (author affiliations) 10 11 12.

Alzheimer's disease and vascular dementia

In Alzheimer's disease the results are mixed. A subgroup analysis of a dose-finding study (133 people with moderate to moderately severe disease) found improved global ratings at all three doses but no significant change in total daily-living scores or the MMSE (randomised trial evidence) 13. In a 197-person trial comparing cerebrolysin, donepezil and both, there were no significant differences between groups in cognition, function or behaviour at 28 weeks, while global outcome favoured cerebrolysin and the combination (randomised trial evidence) 14.

For vascular dementia, one trial in 242 people found cerebrolysin, added to aspirin, improved a cognitive score by 10.6 points against 4.4 on placebo at 24 weeks (randomised trial evidence) 15. A 2019 Cochrane review of six trials (597 people; every trial that reported funding was industry-supported) found courses of cerebrolysin improved cognition and general function, but warned of heterogeneity and high risk of bias, said any benefit may be too small to matter clinically, and called the evidence base weak (systematic review evidence) 16.

UseBest evidenceWhat it found
Acute ischaemic stroke: survivalCochrane review, 7 trials, 1,773 people (2023)Little to no difference in death; more non-fatal serious adverse events
Acute ischaemic stroke: recoveryCASTA, 1,070 people (2012); smaller trialsMain outcome missed in CASTA; smaller trials report benefits
Traumatic brain injuryCAPTAIN I and II, 185 people pooled (2021)Small-to-medium effect on a combined score of many scales
Alzheimer's diseaseTrials of 133 and 197 peopleMixed: better global ratings; no difference against donepezil on cognition
Vascular dementiaCochrane review (2019)Possible small benefit; high risk of bias
Healthy people, 'focus' or memoryTwo small studies (1998, 2000)Brain-wave changes and short-term memory items; no test of everyday memory or focus

Side effects

Across controlled trials, a 2012 safety review found adverse reactions generally mild and short-lived, most often vertigo, agitation and feeling hot, at rates similar to placebo, and no major problems when it was combined with the clot-buster alteplase or with dementia drugs (review of trial data) 17. The 2023 Cochrane review is the important counterweight: in stroke trials, more people on cerebrolysin had non-fatal serious adverse events 1. Our interaction matrix records no published interaction studies 6.

One curiosity: a 2022 case series described five older patients whose grey hair darkened during cerebrolysin treatment, linked to reactivated pigment cells (case series, five people) 18. It is a single report, not a reason to use the drug.

Where it is approved, as of October 27, 2026

Cerebrolysin is not approved by FDA: openFDA's Drugs@FDA and NDC directories had no record of it on October 27, 2026 19. Our regulatory tracker records no product in the UK's electronic medicines compendium and no central EU authorisation, though individual countries can authorise medicines nationally 6. It is widely used for stroke in Russia, Eastern Europe, China and other Asian and post-Soviet countries 5, and its maker is based in Austria 4.

For athletes, cerebrolysin is not named on WADA's Prohibited List. Whether S0, the category for substances with no current approval anywhere, applies depends on whether a national approval elsewhere is current, so we record its status as unsettled; athletes should check with their anti-doping organisation 6.

Questions to ask before using cerebrolysin

  • What condition is it for, and was it tested in people with that condition? (In healthy people, only two small brain-wave studies exist.)
  • How would it be given? The stroke, brain-injury and dementia trials on this page used intravenous infusion.
  • Where does the product come from, and is it the licensed product from a regulated pharmacy?
  • What did the Cochrane review find about serious adverse events, and how does that weigh against the expected benefit?
  • For stroke or brain injury, what does the treating team recommend, given current guidelines where I live?

How it compares with other brain peptides

Other peptides studied for the brain have their own evidence pages: semax, dihexa, and the synthetic stroke peptides nerinetide and sovateltide. Each page sets out its own trials and sources.

The bottom line

Cerebrolysin is used as a medicine in the countries that use it, with a real body of hospital trials. Those trials do not show that it saves lives after stroke, and the Cochrane review found a possible increase in non-fatal serious adverse events. Benefits on recovery scores after stroke and brain injury come from smaller trials, while the one large stroke trial missed its main outcome. As a nootropic for healthy people, the evidence is two small brain-wave studies from 1998 and 2000.

Frequently asked questions

What is cerebrolysin?

A mixture of low-molecular-weight peptides and amino acids made from pig brain, given by intravenous infusion for stroke, brain injury and dementia in parts of Europe and Asia. It is not FDA-approved.

Does cerebrolysin work for stroke?

The 2023 Cochrane review found little to no difference in deaths and more non-fatal serious adverse events. The largest trial missed its main outcome; some smaller trials report better recovery scores.

Is cerebrolysin a nootropic?

Two small studies in healthy people (1998 and 2000) measured brain waves and short-term memory items after it; no trial has tested whether it improves memory or focus in daily life. Its main trials were in people with stroke, brain injury or dementia.

What are cerebrolysin's side effects?

Trials report mostly mild, short-lived vertigo, agitation and feeling hot. In stroke trials pooled by Cochrane, non-fatal serious adverse events were more frequent than with placebo.

Is cerebrolysin legal in the US?

It is not FDA-approved: as of October 27, 2026, FDA's Drugs@FDA and NDC directories had no record of it.

Sources

  1. Ziganshina, L. E., et al. (2023). Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev, 10(10), CD007026. PMID: 37818733
  2. Heiss, W. D., et al. (2012). Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke, 43(3), 630-6. PMID: 22282884
  3. Muresanu, D. F., et al. (2016). Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Stroke, 47(1), 151-9. PMID: 26564102
  4. Gharagozli, K., et al. (2017). Efficacy and safety of Cerebrolysin treatment in early recovery after acute ischemic stroke: a randomized, placebo-controlled, double-blinded, multicenter clinical trial. J Med Life, 10(3), 153-160. PMID: 29075343
  5. Ziganshina, L. E., et al. (2017). Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev, 4(4), CD007026. PMID: 28430363
  6. Grey Peptides encyclopedia entry and regulatory tracker for cerebrolysin: FDA status (not approved, read October 1, 2026), UK EMC and EMA register results (read October 3, 2026), WADA status (S0 unsettled), interaction coverage. Read October 3, 2026.
  7. Zhang, C., et al. (2010). Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcome after stroke. J Neurosci Res, 88(15), 3275-81. PMID: 20857512
  8. Funke, M., et al. (1998). Dose-dependent effects of Cerebrolysin on EEG and short-term memory of healthy volunteers during control and hyperventilation induced cerebral ischemia. J Neural Transm Suppl, 53, 385-98. PMID: 9700674
  9. Alvarez, X. A., et al. (2000). Oral Cerebrolysin enhances brain alpha activity and improves cognitive performance in elderly control subjects. J Neural Transm Suppl, 59, 315-28. PMID: 10961443
  10. Poon, W., et al. (2020). Safety and efficacy of Cerebrolysin in acute brain injury and neurorecovery: CAPTAIN I-a randomized, placebo-controlled, double-blind, Asian-Pacific trial. Neurol Sci, 41(2), 281-293. PMID: 31494820
  11. Muresanu, D. F., et al. (2020). Efficacy and safety of cerebrolysin in neurorecovery after moderate-severe traumatic brain injury: results from the CAPTAIN II trial. Neurol Sci, 41(5), 1171-1181. PMID: 31897941
  12. Vester, J. C., et al. (2021). Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series. Neurol Sci, 42(11), 4531-4541. PMID: 33620612
  13. Alvarez, X. A., et al. (2011). Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin. Eur J Neurol, 18(1), 59-68. PMID: 20500802
  14. Alvarez, X. A., et al. (2011). Combination treatment in Alzheimer's disease: results of a randomized, controlled trial with cerebrolysin and donepezil. Curr Alzheimer Res, 8(5), 583-91. PMID: 21679156
  15. Guekht, A. B., et al. (2011). Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial. J Stroke Cerebrovasc Dis, 20(4), 310-8. PMID: 20656516
  16. Cui, S., et al. (2019). Cerebrolysin for vascular dementia. Cochrane Database Syst Rev, 2019(11). PMID: 31710397
  17. Thome, J., et al. (2012). Safety profile of Cerebrolysin: clinical experience from dementia and stroke trials. Drugs Today (Barc), 48 Suppl A, 63-9. PMID: 22514795
  18. Villarreal-Reyna, G., et al. (2022). Cerebrolysin induces hair repigmentation associated to MART-1/Melan-A reactivation. Eur J Med Res, 27(1), 257. PMID: 36411485
  19. US FDA, openFDA Drugs@FDA and NDC directory endpoints, searched for 'cerebrolysin' October 27, 2026 (api.fda.gov): no matching record. Cited without a link.

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.

All articles

New guides and rule changes, by email

One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.

We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead